Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_3
1
10%
Ph phase_1
4
40%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
4(40.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (40.0%)
Phase 25 (50.0%)
Phase 31 (10.0%)

Trials by Status

terminated110%
withdrawn110%
completed880%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_1

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

NCT00733187
completedphase_1

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

NCT00718380
completedphase_2

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

NCT00707889
completedphase_2

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00716534
completedphase_2

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00733187Phase 1

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Completed
NCT00718380Phase 1

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Completed
NCT00707889Phase 2

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Completed
NCT00716534Phase 2

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT00645177Phase 2

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Completed
NCT00486538Phase 2

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Completed
NCT00517920Phase 2

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Completed
NCT01009593Phase 3

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Terminated
NCT01114191Phase 1

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)

Completed
NCT00754104Phase 1

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10